A bidding war over U.S. biotech Metsera was coming to a head on Thursday, with Danish drugmaker Novo Nordisk locked in a $10 ...

After a company-wide restructuring costing some DKK 9 billion ($1.38 billion), Novo’s path to success lies in its ability to ...

Metsera on Tuesday called Novo Nordisk’s new $10 billion offer “superior” to rival Pfizer's bid of $8 billion.

Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, while some House Republicans warm to ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year forecasts on Wednesday as sales growth of its ...

According to Reuters, Lilly could offer the lowest dose of its popular weight loss drug Zepbound at $149 a month, and Novo’s ...

Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being ...

Pfizer plans to sweeten its bid for Metsera , a person familiar with the matter told Reuters, after a judge denied its ...

Pressure from the FTC and Pfizer is building around Novo Nordisk’s bid to snatch obesity biotech Metsera: The antitrust ...

The court’s decision allows Metsera to walk away from its previous acquisition agreement with Pfizer in favor of Novo Nordisk ...

Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that ...

Pfizer – which first agreed a $4.9 billion takeover deal with Metsera in September – has argued that the rival bid is ...